Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026

Zenas BioPharma, Inc. (NASDAQ: ZBIO) will present new data from its Phase 3 INDIGO trial evaluating obexelimab for immunoglobulin G4-related disease (IgG4-RD) at two upcoming scientific meetings: the 6th International Symposium on IgG4-Related Disease from October 8-10, 2026, and the American College of Rheumatology (ACR) Convergence 2026 from November 6-11, 2026. The presentations will include longer-term flare protection and safety data, as well as analyses on glucocorticoid-associated toxicity and vaccine responses in patients treated with obexelimab.